Some biotech rallies are built on vague hope and a few carefully polished slides. This one has a much cleaner reason for the move.
Tango just reported early pancreatic cancer data that looked far stronger than investors expected, and the market reacted exactly the way you would expect when a small-cap biotech suddenly looks like it may have a real shot at a very tough cancer.
Hidden Tax Breaks (Sponsored)
Capital gains taxes may quietly reduce more of your investment returns than you realize.
But the tax code includes several strategies that may help reduce that bill.
Three often-overlooked areas include investment-related expenses, cost basis adjustments, and real estate selling costs.
When structured correctly, these deductions may help minimize taxable gains.
Because the rules can be complex, many investors work with fiduciary financial advisors to plan tax-efficient strategies.
Use SmartAsset’s free tool to find vetted financial advisors serving your area.
What Just Happened
The data lit the fuse
Tango Therapeutics, Inc. (NASDAQ: TNGX) surged after reporting initial Phase 1/2 data for vopimetostat in combination with Revolution Medicines’ daraxonrasib in MTAP-deleted, RAS-mutant metastatic pancreatic ductal adenocarcinoma.
The headline number was the reason for the explosion. The combination showed a 92% objective response rate in pancreatic cancer, with responses in 11 of 12 evaluable patients.
Disease control was 100%, and the six-month progression-free survival rate was 90%, with median progression-free survival not yet reached.
For pancreatic cancer, that is the kind of early signal that gets investors’ attention fast.
The stock reacted like a biotech rocket
TNGX jumped more than 50% on the news and closed at a record high.
The stock is now up more than 600% over the past year based on the figures you shared, which means this has already moved from hidden biotech story to full-blown momentum trade.
That kind of move demands discipline. But it also tells you the market believes the data may have changed the company’s trajectory.
Analysts moved quickly
Wolfe Research upgraded Tango to Outperform and set a $35 target after the data, saying the dataset looked better than expected and created a new benchmark in MTAP-deleted pancreatic cancer.
Other target estimates also moved higher, with the average price target rising to about $36.91 and the broad consensus still sitting at Buy.
That analyst response matters because this is not just retail excitement. The Street is starting to underwrite a bigger opportunity.
Why The Business Matters
This is a targeted cancer story
Tango develops cancer therapies aimed at tumor-specific vulnerabilities.
Vopimetostat is designed for cancers with MTAP deletions, a genetic feature found in several tumor types, including pancreatic cancer and non-small cell lung cancer.
The strategy is simple in concept but powerful if it works: find a weakness that cancer cells depend on, then target it more precisely than traditional chemotherapy.
Pancreatic cancer is a brutal market
Pancreatic ductal adenocarcinoma is one of the hardest cancers to treat. Outcomes are poor, treatment options are limited, and new approaches are badly needed.
That is why this data matters so much. A strong response signal in pancreatic cancer carries more weight than the same kind of signal in an easier disease area. Investors know the unmet need is enormous.
Poll: When evaluating management quality, what carries the most weight for you?
Savings Losing Ground (Sponsored)
Inflation keeps rising… but most banks still pay savers next to nothing.
Meanwhile, major financial institutions have quietly used a strategy averaging 29% yearly.
Since 2000, it turned $1,000 into over $556,000.
See how “The 29% Account” works before more Americans catch on.
The Revolution Medicines link strengthens the setup
Tango’s vopimetostat is being combined with Revolution Medicines’ daraxonrasib, a RAS(ON) inhibitor that has already generated major attention in pancreatic cancer.
Daraxonrasib is becoming an important backbone therapy candidate, and Tango may have found a way to make that backbone more powerful in MTAP-deleted tumors.
That is the bigger strategic point. Tango is not trying to build the entire treatment paradigm alone.
It is attaching its drug to one of the most watched targeted cancer programs in the space.
Elite Trade Club Insider
$68 Million In Insider Selling Just Hit Two Broken Charts
You’re watching two beaten-up charts from the outside, trying to decide whether the pullback is a warning or an opportunity. But Elite Trade Club Insider readers are getting the cleaner read: insiders and major holders are still selling into the weakness before most investors have figured out what the filings are saying.
You’re reading the free version. Here’s what we held back.
Every day, insiders and institutions move millions before the market catches on. We surface the data behind those moves before the rest of the market sees it.
A subscription gets you:
The insider buys, options bets, and dark pool moves the free edition can't show you. Unlocked every weekday.
A Sunday Deep Dive that tells you where to look before Monday's bell rings.
The Friday Smart Money Brief: who bought, who sold, where the big options bets landed, and where institutions are hiding volume. Three data layers. One email.
A Monthly Insider Scorecard so you always know whether smart money is buying or selling the market.
Every past Insider edition, unlocked, on elitetrade.club. Go back and see what you missed.
$25/mo or $250/yr. 30-day money back guarantee. Cancel anytime. Founding member pricing: lock in $25/mo before we raise it.
Why The Stock Has A Case
The response rate is hard to ignore
A 92% objective response rate in advanced pancreatic cancer is the central reason to care. Yes, the dataset is small.
Yes, it needs confirmation. But in biotech, early response signals this strong can completely change how investors value a program.
This is exactly the kind of data that can support a momentum trade while the company moves toward larger studies.
Phase 3 is now in view
Tango said the data support rapid advancement of vopimetostat plus daraxonrasib into Phase 3 development in first-line MTAP-deleted pancreatic cancer.
That is important because it moves the story from interesting early signal to a clearer registrational path.
Biotech stocks rerate when investors can see the next step. Tango now has that.
Lung cancer adds optionality
The pancreatic cancer data drove the move, but the lung cancer signal also helps.
The vopimetostat plus daraxonrasib combination produced confirmed objective responses in all three evaluable non-small cell lung cancer patients in the early cohort.
That is too small to build the full case around, but it adds upside optionality. If the drug works across multiple MTAP-deleted tumor types, the commercial opportunity gets much larger.
High-Rated AI (Sponsored)
Louis Navellier’s proprietary Stock Grader system helped flag major winners years before they became household names.
Now, that same $9 million system is flashing its highest rating on one AI stock with 28% year-over-year sales growth and more than 30,000 patents.
He is giving away the name, ticker, and full analysis for free.
See the free AI stock pick here.
What Has To Go Right
The data need to hold up in larger studies
This is the big one. Twelve pancreatic cancer patients is not enough to declare victory.
Tango needs to show the response rate, progression-free survival, and safety profile remain strong in a larger, more controlled trial.
Phase 3 design needs to be clean
The next trial needs the right patient population, endpoint, comparator, and partner alignment with Revolution Medicines.
A clean Phase 3 plan will help investors stay confident that the early signal can become a real approval path.
Safety needs to stay manageable
Tango said the vopimetostat combinations were generally well tolerated, with no related Grade 4 or Grade 5 adverse events or treatment discontinuations due to adverse events reported in the release.
That is encouraging, but safety will matter more as the dataset grows.
What Could Trip It Up
The sample size is tiny
This is the main risk. The data are exciting, but they are still early. Small oncology datasets can look amazing and then normalize as more patients enroll. Investors need to respect that.
The stock has already exploded
TNGX is up more than 600% over the past year. That means a lot of optimism is already priced in. Any disappointment, delay, safety issue, or weaker follow-up data can hit the stock hard.
Strategy risk is real
Not every analyst loved the development shift. Piper Sandler downgraded the stock to Neutral after the company leaned more heavily into the RAS combination approach, while Jefferies also moved to Hold even as it raised its target.
That tells you the Street is excited, but not unanimous.
What I’d Watch Next
The first thing to watch is the Phase 3 plan for vopimetostat plus daraxonrasib in first-line MTAP-deleted pancreatic cancer. The second is any updated durability data from the current Phase 1/2 trial.
The third is the lung cancer cohort, because additional responses there would broaden the story. The fourth is whether analysts keep raising targets after digesting the data and trial design.
My Take
Buy on biotech momentum. Tango is not a safe stock, and it is not a normal valuation story.
But the data are strong enough to justify the move, the program now has a clearer Phase 3 path, and pancreatic cancer is a high-need market where strong early efficacy can drive major investor interest.
The key risk is that the dataset is still small. If the response rate weakens in a larger trial or safety becomes more complicated, the stock can fall quickly.
But right now, the momentum is supported by unusually strong early data, analyst upgrades, and a much bigger strategic opportunity than the market was pricing in a week ago.
Action Recap
🧬 Looking to buy? Buy on biotech momentum, but size it carefully. This is a high-risk, high-upside clinical data trade.
📈 Already own it? Keep holding while the Phase 3 path and analyst support remain intact.
⚠️ Main risk to respect: The early data are impressive but small. Larger studies need to confirm the signal.
That’s all for today. Thank you for reading. If you have any feedback, please reply to this email.
Best Regards,
— Adam Garcia
Elite Trade Club
Click here to get our daily newsletter straight to your cell for free.
P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP.
